text
stringlengths 0
197k
|
|---|
Innovative Non-Drug Solutions: To improve participation in non-medication pain relief methods, we suggest incorporating gaming elements into these programs (GAP). Originating in digital media in 2008, gamification has since spread across various industries. It involves adding game-like elements to activities to boost engagement, experience, and motivation. |
Project Goals: The aims of this initiative include creating a web-based Gamified Pain Management Program (GAP), engaging older adults with chronic pain in the development of GAP, and gathering their feedback on the program's effectiveness. conditions: Chronic Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 4 type: ESTIMATED name: Gamified web-based pain management Program measure: Pain Relief sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hong Kong Metropolitan University status: RECRUITING city: Hong Kong country: Hong Kong name: Mimi Mun Yee Tse, PhD. role: CONTACT phone: (852)39708764 email: [email protected] name: Mimi Mun Yee Mimi Mun Yee, PhD. role: PRINCIPAL_INVESTIGATOR name: Tyrone Tai On Kwok, PhD. role: SUB_INVESTIGATOR name: Timothy Chung Ming Wu, Master role: SUB_INVESTIGATOR lat: 22.27832 lon: 114.17469 hasResults: False |
<|newrecord|> nctId: NCT06387693 id: 24U-1359 briefTitle: Artificial Intelligence in ANOCA acronym: (AI)NOCA overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2028-08 date: 2028-12 date: 2024-04-29 date: 2024-04-29 name: UMC Utrecht class: OTHER briefSummary: Angina pectoris is diagnosed in \>180.000 people in the Netherlands each year. Diagnosis in angina pectoris focuses on epicardial coronary stenosis, the identification of which may lead to guideline-directed medical therapy or revascularization. However, no such stenosis is identified in 40-70% of patients. This condition, angina with no obstructed coronary artery (ANOCA), is more prevalent in women and is related to poor quality of life, high medical expenses, and a higher incidence of adverse events. |
The origin of ANOCA can be evaluated during invasive coronary angiography by coronary function testing (CFT) to identify coronary vasomotor disorders. This relates to vasospasm of the coronary artery and microcirculation, or to impaired microvascular vasodilation. For the diagnosis of vasospasm, CFT needs to result in electrocardiographic signs of myocardial ischemia as part of the diagnostic criteria. This is a critical point in the diagnosis of vasospasm, as these signs can be subtle and can vary, and are therefore prone to misinterpretation. Apart from this caveat, the diagnosis approach therefore currently requires an invasive procedure for the diagnosis. This limits the broad application and hampers early identification and treatment of ANOCA. |
During CFT, a coronary guide wire is routinely advanced in the coronary artery which also allows obtaining an intracoronary ECG by attaching a sterile alligator clamp to a standard electrocardiogram lead. This allows continuous recording of intracoronary ECG throughout CFT on the same monitor as the routine ECG. This technique can increase sensitivity for myocardial ischemia during CFT. Further, Holter ECG monitoring allows the identification of ischemic changes in the ECG in the outpatient setting. Evidence is lacking on the patterns of myocardial ischemia that occur during spontaneous angina pectoris symptoms in ANOCA patients, and on the sensitivity of Holter ECG for this purpose. Finally, the interpretation of ischemic patterns on ECG tracings can be cumbersome, especially when changes are subtle or change from beat to beat. The use of deep learning techniques allows to automate the interpretation of ECG traces and may improve the standardized diagnosis in ANOCA. conditions: Angina, Stable studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 250 type: ESTIMATED name: Holter monitoring, intracoronary ECG measure: Prevalence of myocardial ischemia in patients with equivocal coronary function test results measure: Diagnostic accuracy of perprocedural Holter ECG monitoring to diagnose coronary vasomotor disorders measure: Diagnostic ccuracy of outpatient Holter monitoring for coronary vasomotor disorders sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06387680 id: 2022/187 briefTitle: The Peanut Ball Use on Labor overallStatus: COMPLETED date: 2023-01-01 date: 2024-03-01 date: 2024-04-01 date: 2024-04-29 date: 2024-04-29 name: Selcuk University class: OTHER briefSummary: The purpose of this study was to evaluate the effect of using peanut balls during labor on labor memory, labor satisfaction, labor length, and neonatal APGAR scores. conditions: Birth Outcome, Adverse conditions: Birth, First conditions: Labor Long conditions: Apgar; 4-7 at 1 Minute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 140 type: ACTUAL name: The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial measure: Comparison of sociodemographic of pregnant women. measure: Comparison of obstetric characteristics of pregnant women measure: Comparison of postpartum characteristics of pregnant women measure: Comparison of duration of 1st and 2nd stage of labor by group measure: Comparison of 1st and 5th minute APGAR scores of newborns by group measure: Comparison of the mean scores of the Pregnant Women's Birth Memory and Recall Questionnaire (BirthMARQ) and its subscales by groups measure: Comparison of pregnant women's Birth Satisfaction Scale (BSS) mean scores by groups sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Selcuk University city: Konya zip: 42250 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False |
<|newrecord|> nctId: NCT06387667 id: FIRTI briefTitle: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-01 date: 2026-06-01 date: 2024-04-29 date: 2024-04-29 name: New Valley University class: OTHER briefSummary: Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance. conditions: Immunocompromised ICU Patients With Respiratory Tract Infections studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Immunocompromised ICU Patients with Respiratory tract infections primaryPurpose: DIAGNOSTIC masking: NONE count: 250 type: ESTIMATED name: Complete blood count name: C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT) name: CT chest name: Microscopic examination name: culture and sensitivity measure: Number of fungal species causing pneumonia in immunocompromised ICU patients measure: Determine the antifungal susceptibility profiles of the identified fungal isolates. measure: Number of associated specific patient factors with the type or antifungal resistance of fungal infections sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06387654 id: RC31/23/0361 briefTitle: Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases acronym: TekAPo overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-04 date: 2034-04 date: 2024-04-29 date: 2024-04-29 name: University Hospital, Toulouse class: OTHER briefSummary: The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies. conditions: Autoimmune Bullous Dermatosis conditions: Systemic Autoimmune Diseases With Dermatological Presentation conditions: Dysimmune Dermatological Diseases conditions: Auto-inflammatory Dermatological Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 800 type: ESTIMATED name: Blood sampling name: Remainders of samples taken as part of the treatment measure: Building a collection of biological samples and clinical-biological data from patients with autoimmune, dysimmune or auto-inflammatory dermatological disease measure: Identification of new autoantibodies measure: Identification of biomarkers regarding the severity (such as cytokines, survival factors) in order to help the therapeutic decisions measure: Exploration of the pathophysiological mechanisms of rare autoimmune dermatological pathologies measure: Comparison of blood cells populations determinants with flow cytometry, before and after cell therapy and in patients responder or not responder to cell therapy sex: ALL minimumAge: 6 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Purpan University Hospital city: Toulouse zip: 31059 country: France name: Chloé BOST, MD, PhD role: CONTACT phone: 5 61 77 61 44 phoneExt: 0033 email: [email protected] lat: 43.60426 lon: 1.44367 hasResults: False |
<|newrecord|> nctId: NCT06387641 id: 2024004 briefTitle: Effects of Life Review Intervention on Meaning in Life Among Older Adults With Disabilities overallStatus: ENROLLING_BY_INVITATION date: 2024-03-25 date: 2025-01-01 date: 2025-01-01 date: 2024-04-29 date: 2024-04-29 name: Bao Huimin class: OTHER briefSummary: The goal of this interventional study is to learn if life review works to improve the sense of meaning in life in older adults with disabilities who live at home. The main questions it aims to answer are: |
Does life review enhance the sense of meaning in life of participants? Dose life reviews enhance the life satisfaction of participants. Dose life reviews enhance the quality of life of participants? |
Researchers will compare the life review program to routine community health services to see if the life review intervention program is effective in enhancing the sense of meaning in life of older adults with disabilities who live at home. |
Participants will: |
Take face-to-face life review interview or routine community health service every week for 6 weeks. |
Take the the questionnaire survey before and after the six-week life review intervention. conditions: Disabilities, Psychological studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 68 type: ESTIMATED name: Life review name: Routine community health services measure: Change from Baseline in Meaning in life on the Meaning in Life Questionnaire (MLQ) at Week6 measure: Change from Baseline in Life satisfaction on the Life Satisfaction In-dex A (LSIA) at Week6 measure: Change from Baseline in Quality of life on the 12-Item Short Form Survey (SF-12) at Week6 sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xixi Street Community Health Service Center city: Hanzhou state: Zhejiang zip: 310012 country: China lat: 26.4965 lon: 99.437 facility: Gongchenqiao Street Community Health Service Centre city: Hanzhou state: Zhejiang zip: 310015 country: China lat: 26.4965 lon: 99.437 facility: Baiyang Street Wenchao Community Health Centre city: Hanzhou state: Zhejiang zip: 310018 country: China lat: 26.4965 lon: 99.437 facility: School of Nursing, Hangzhou Normal University city: Hanzhou state: Zhejiang zip: 311121 country: China lat: 26.4965 lon: 99.437 hasResults: False |
<|newrecord|> nctId: NCT06387628 id: LM108-IIT-202 briefTitle: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer overallStatus: RECRUITING date: 2024-06-01 date: 2026-04-01 date: 2027-04-01 date: 2024-04-29 date: 2024-04-29 name: Fudan University class: OTHER briefSummary: To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer. conditions: TNBC - Triple-Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 74 type: ESTIMATED name: LM-108 name: Toripalimab name: Eribulin name: Nab paclitaxel measure: ORR measure: DoR measure: DCR measure: PFS measure: OS measure: Adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Biyun Wang role: CONTACT phone: 18017312387 email: [email protected] lat: 31.22222 lon: 121.45806 hasResults: False |
<|newrecord|> nctId: NCT06387615 id: H22086 id: 1R21HD108576-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R21HD108576-01A1 briefTitle: Impact of Non-invasive Brain Stimulation on Learning Novel Spoken Words overallStatus: RECRUITING date: 2024-01-01 date: 2024-10-31 date: 2025-12-31 date: 2024-04-29 date: 2024-04-29 name: Georgia State University class: OTHER name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) briefSummary: The purpose of the proposed study is to use transcranial magnetic stimulation (TMS) to evaluate a neurobiological model of spoken word learning in older youth. Specifically, it is hypothesized that: (1) inhibition of the left dorsal stream will impact subsequent learning, processing, and retention of phonologically similar pseudowords; (2) the impact of dorsal stream inhibition on word learning will be associated with baseline levels of variability in neural activity, indicative of underlying differences in cortical excitability. conditions: Dyslexia conditions: Dyslexia, Developmental conditions: Learning; Developmental Disorder, Reading studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Active cTBS name: Sham measure: Novel Word Learning Task measure: Pseudoword Discrimination Task measure: MRI Scan sex: ALL minimumAge: 16 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT facility: Georgia State University/Georgia Tech Center for Advanced Brain Imaging (CABI) status: RECRUITING city: Atlanta state: Georgia zip: 30318 country: United States name: C.Nikki Arrington, PhD role: CONTACT phone: 404-385-8621 lat: 33.749 lon: -84.38798 hasResults: False |
<|newrecord|> nctId: NCT06387602 id: FUI/CTR/2024/6 briefTitle: Comparison Between Effects of Active Release Technique and Post Isometric Relaxation on Adductor Strain in Mixed Martial Arts Fighters overallStatus: RECRUITING date: 2023-07-15 date: 2023-11-20 date: 2024-11-20 date: 2024-04-29 date: 2024-04-29 name: Foundation University Islamabad class: OTHER briefSummary: This study is a randomized controlled trial and the purpose of this study is to compare the effects between active release technique and post-isometric relaxation on adductor strain in mixed martial arts fighters. conditions: Adductor Strain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Cryotherapy name: Strengthening of adductors name: Active release technique name: Post-Isometric Relaxation measure: Pain Intensity measure: Range of motion measure: Functionality measure: Flexibility sex: ALL minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: Foundation University College of Physical Therapy status: RECRUITING city: Rawalpindi state: Punjab zip: 46000 country: Pakistan name: Furqan Yaqoob, MS-OMPT,PHD* role: CONTACT phone: 03465333101 email: [email protected] lat: 33.6007 lon: 73.0679 hasResults: False |
<|newrecord|> nctId: NCT06387589 id: FUI/CTR/2024/5 briefTitle: Effects of Static Stretching Versus Post Facilitation Stretch of Iliopsoas in Non-Specific Low Back Pain overallStatus: RECRUITING date: 2023-07-15 date: 2023-11-20 date: 2024-06-20 date: 2024-04-29 date: 2024-04-29 name: Foundation University Islamabad class: OTHER briefSummary: This study is a randomized controlled trial and the purpose of this study is to determine the effects of Static Stretching Versus Post Facilitation Stretch of Iliopsoas combined with core stability exercises in Non-Specific Low Back Pain" conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Core stability exercises name: Static Stretching of Iliopsoas name: Post Facilitation Stretch of Iliopsoas measure: Pain intensity measure: Level of disability measure: Lumbar Range of motion measure: Hip Range of motion sex: ALL minimumAge: 30 Years maximumAge: 50 Years stdAges: ADULT facility: Foundation University College of Physical Therapy status: RECRUITING city: Rawalpindi state: Punjab zip: 46000 country: Pakistan name: Sana Khalid, MSNMPT,PHD role: CONTACT phone: 03315050460 email: [email protected] lat: 33.6007 lon: 73.0679 hasResults: False |
<|newrecord|> nctId: NCT06387576 id: Post-discharge Appointments briefTitle: Post-Discharge Follow-up Appointment Scheduling overallStatus: RECRUITING date: 2024-04-08 date: 2024-05 date: 2024-06 date: 2024-04-29 date: 2024-04-29 name: University of California, Los Angeles class: OTHER briefSummary: This is a prospective clinical trial evaluating whether a behaviorally informed intervention (pre-discharge iPad video scheduling) increases post-discharge primary care physician (PCP) appointment completion compared to the status-quo scheduling process (post-discharge via phone), with the ultimate goal of improving patient health outcomes. conditions: Appointments and Schedules studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel-arm control trial primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: PARTICIPANT count: 300 type: ESTIMATED name: Behaviorally informed pre-discharge iPad video scheduling measure: Post-discharge follow-up PCP appointment completion rate within 7 days measure: Post-discharge follow-up PCP appointment completion rate within 14 days measure: Post-discharge follow-up PCP appointment scheduling rate within 7 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UCLA Santa Monica Medical Center status: RECRUITING city: Santa Monica state: California zip: 90404 country: United States name: Rich Leuchter, MD role: CONTACT phone: 310-825-9111 email: [email protected] lat: 34.01945 lon: -118.49119 hasResults: False |
<|newrecord|> nctId: NCT06387563 id: FUI/CTR/2024/4 briefTitle: Effects of Abdominal Muscle Activation Training, Using Pressure Biofeedback in Comparison With Surface Electromyography overallStatus: RECRUITING date: 2023-11-06 date: 2024-05-01 date: 2024-05-30 date: 2024-04-29 date: 2024-04-29 name: Foundation University Islamabad class: OTHER briefSummary: This study is a randomized control trial and the purpose of this study to determine the effects of abdominal muscle activation training on non-specific low back pain; using pressure biofeedback in comparison with surface electromyography biofeedback: a randomized control trial. conditions: Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized control trial primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Abdominal activation using pressure biofeedback name: Abdominal activation using SEMG biofeedback measure: Pain Intensity measure: Level of Disability sex: ALL minimumAge: 18 Years maximumAge: 44 Years stdAges: ADULT facility: Foundation University College of Physical Therapy status: RECRUITING city: Rawalpindi state: Punjab zip: 46000 country: Pakistan name: Anam Rehman, MS-OMPT role: CONTACT phone: 03355082299 email: [email protected] lat: 33.6007 lon: 73.0679 hasResults: False |
<|newrecord|> nctId: NCT06387550 id: FUI/CTR/2024/3 briefTitle: Effects of Eccentric Training on Glycemic Control and Quality of Life in Patients With Type II Diabetes Mellitus overallStatus: RECRUITING date: 2024-03-20 date: 2024-07-01 date: 2024-07-15 date: 2024-04-29 date: 2024-04-29 name: Foundation University Islamabad class: OTHER briefSummary: Diabetes is defined by the level of hyperglycemia its a metabolic chronic disorder that furthur lead to life threatning medical conditions however, the prevalence of diabetes is rapidly increasing day by day in both developed and developing countries making it global pandemic and type II is more prevalent. Life dependency is increased due to long term effects of diabetes in specifically older individuals. Physical activity and exercise improves glucose tolerance and also reduces other life threatening diabetic complications, improving the quality of life in diabetic population. conditions: Type II Diabetes Mellitus studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a pre-post quasi experimental study having one group analysis.Participants will be selected through inclusion and exclusion criteria then pre assessment would be done that include HBA1C and EQ5DL QOL tool, followed by intervention and post assessment. primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Eccentric Training measure: Glycemic control measure: Patient's quality of life sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Foundation University College of Physical Therapy status: RECRUITING city: Rawalpindi state: Punjab zip: 46000 country: Pakistan name: Zara Khalid, PhD* role: CONTACT phone: +923335415822 email: [email protected] lat: 33.6007 lon: 73.0679 hasResults: False |
<|newrecord|> nctId: NCT06387537 id: FUI/CTR/2024/2 briefTitle: Effects of Scapular Mobilization on Shoulder Proprioception and Pain in Patients With Adhesive Capsulitis overallStatus: RECRUITING date: 2024-03-01 date: 2024-07-01 date: 2024-07-15 date: 2024-04-29 date: 2024-04-29 name: Foundation University Islamabad class: OTHER briefSummary: Adhesive capsulitis is a common musculoskeletal condition. Painful gradual loss of both active and passive gleno-humeral motion resulting from progressive fibrosis and ultimate contracture of the gleno-humeral joint capsule.Scapular position and movement perception both effected by shoulder adhesive capsulitis, change in the scapular kinematics in the form of an increase in scapular lateral rotation, and reduced joint sense for shoulder movements in adhesive capsulitis. Physiotherapists have a wide range of options in managing Adhesive capsulitis including Electrotherapeutic modalities, kaltenborn mobilization, Maitland's mobilization,Mulligan's mobilization and Manipulation. So far studies have shown the efficacy of different treatments in combination or in isolation.Few studies on proprioception in rotator cuff tear, sub acromial impingment syndrome, but no obseved effects of scapular mobilization on shoulder proprioception in patients with adhesive capsulitis.Physical therapist focus on lowering pain and ROM limitations in the shoulder,but often neglect to evaluate proprioception/joint position sense as well as the roleof scapula in adhesive capsulitis during treatment.If found effective,this study can help in probviding treatment protocols for improving proprioception in patients with adhesive capsulits. conditions: Adhesive Capsulitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomized controlled trial having two groups. One group will receive conventional physical therapy and the second will receive conventional physical therapy along with scapular mobilization. Both groups will be recruited concurrently. primaryPurpose: PREVENTION masking: NONE count: 30 type: ESTIMATED name: Conventional physical therapy name: Scapular mobilization. measure: Shoulder Proprioception measure: Pain Intensity measure: Shoulder Range of motion measure: Shoulder Disability sex: ALL minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Foundation University College of Physical Therapy status: RECRUITING city: Rawalpindi state: Punjab zip: 460000 country: Pakistan name: Zara Khalid, DPT, MS-CPPT,PHD* role: CONTACT phone: +923335415822 email: [email protected] lat: 33.6007 lon: 73.0679 hasResults: False |
<|newrecord|> nctId: NCT06387524 id: FUI/CTR/2024/1 briefTitle: Effects of Eccentric Exercises on Gait Parameters in Patellofemoral Pain Syndrome: A Quasi-Experimental Study overallStatus: RECRUITING date: 2023-07-15 date: 2024-11-20 date: 2024-11-20 date: 2024-04-29 date: 2024-04-29 name: Foundation University Islamabad class: OTHER briefSummary: This study is a quasi experimental and the purpose of this study is to determine the effects of eccentric exercises on gait parameters in patellofemoral pain syndrome: a quasi - experimental study conditions: Patellofemoral Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Quasi experimental study primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: McConnell Taping name: ECCENTRIC EXERCISES: measure: Dynamic knee valgus angle measure: Hip Range of Motion measure: Knee Range of Motion measure: Pain intensity measure: Gait Speed measure: Cadence measure: Stride length measure: Step length measure: Cycle length sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Foundation University College of Physical Therapy status: RECRUITING city: Rawalpindi state: Punjab zip: 46000 country: Pakistan name: Qurat ul Ain Saeed, MS-OMPT,PHD* role: CONTACT phone: 03315562889 email: [email protected] lat: 33.6007 lon: 73.0679 hasResults: False |
<|newrecord|> nctId: NCT06387511 id: NutriVax-Measles briefTitle: Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-15 date: 2025-06-15 date: 2024-04-29 date: 2024-04-29 name: Alliance for International Medical Action class: OTHER name: Institut National de la Santé Et de la Recherche Médicale, France name: Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire name: Yobe State Ministry of Health, Nigeria name: Eleanor Crook Foundation name: Gavi, The Vaccine Alliance briefSummary: Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services. |
We will estimate 1) the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in terms of measles vaccine coverage, after 12 months of program implementation, 1) in children aged 12-23 months in the endline cross-sectional household survey, 2) in children aged 6-12 months at inclusion in a longitudinal 12 months follow-up survey. |
Secondary objectives are to assess the barriers and facilitators from the perspectives of parents/legal guardian of children, health care providers and community health workers and to assess the cost-efficiency of the |
This study will implrmented in 20 wards covering the Karasuwa and Nguru Local Government Areas (LGAs) in Yobe state, Northeast Nigeria. |
This is a pragmatic parallel cluster randomized trial (PCT) with baseline measure with different populations and data collection modes: 1) baseline and endline cross-sectional household surveys of children aged 12-23 months, 2) a longitudinal follow-up survey (LS) of children aged 6-12 months at inclusion, 3) a qualitative feasibility and acceptability survey of parents of children aged 6-23 months, of health providers, of community health workers and community representatives and 4) a cost survey of parents/legal guardian of children from the longitudinal follow-up cohort, and 5) a health facility cost survey of a randomized sub-sample of health facilities. |
Clusters will be randomly allocated at a ratio of 1:1 either to the standard arm or to the NutriVax arm: |
* The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts, named the standard EPI arm; |
* The NutriVax program combining the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres (i.e. PHCCs) and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres (i.e. PHCCs) for children 6-23 months of age, named the NutriVax arm. conditions: Immunization Coverage Improvment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A two arms opened pragmatic parallel cluster-randomized controlled trial with baseline measure primaryPurpose: PREVENTION masking: NONE maskingDescription: No possible to mask intervention due to the specifity of the intervention tested count: 3720 type: ESTIMATED name: Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax measure: Measles vaccine coverage in children aged 12-23 months measure: Measles vaccine coverage in children 6-12 months at inclusion measure: Measles vaccine coverage: at least one dose measure: Measles vaccine coverage : two doses measure: Timeliness of measles 1 vaccination measure: Other infant vaccines coverage measure: Zero-dose measure: Fully immunization measure: Acceptability measure: Cost-efficiency sex: ALL minimumAge: 6 Months maximumAge: 23 Months stdAges: CHILD hasResults: False |
<|newrecord|> nctId: NCT06387498 id: 20-2286 briefTitle: Testicular Tissue Cryopreservation (TTC) acronym: TTC overallStatus: RECRUITING date: 2020-09-28 date: 2027-12-30 date: 2027-12-30 date: 2024-04-29 date: 2024-04-29 name: University of Colorado, Denver class: OTHER briefSummary: The "Testicular Tissue Cryopreservation" study is open to a subset of patients facing disease or treatment regimens that could lead to infertility (gonadotoxic therapies). For some of these patients, experimental testicular tissue cryopreservation is the only fertility preservation option available. The overall objective of this study is to determine the feasibility and acceptability of testicular tissue cryopreservation in male patients of all ages who have a condition or will undergo a treatment that can cause infertility. conditions: Fertility Issues studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: Testicular tissue biopsy and cryopreservation measure: Feasibility, as Assessed via the Percentage of Eligible Patients who do a Procedure measure: Feasibility, as Assessed via Percentage of Patients who Attempted a Procedure who were able to Cryopreserve measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified measure: Safety, as Assessed via the Number of Participants with At Least One Pre-specified measure: Acceptability, as Assessed via Annual Survey Regret Score sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Jocelyn Phipers, RN role: CONTACT phone: 303-724-7807 email: [email protected] name: Leslie Appiah, MD role: CONTACT email: [email protected] name: Leslie Appiah, MD role: PRINCIPAL_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False |
<|newrecord|> nctId: NCT06387485 id: SR-001 briefTitle: A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2025-04-01 date: 2024-04-29 date: 2024-04-29 name: Ricoh USA, Inc. class: INDUSTRY briefSummary: This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body. The study is expected to last approximately 12 months and involve up to 150 subjects across 3 sites. Subjects will be randomized in a 1:1 ratio into either the experimental arm, utilizing 3D printed models and imaging, or the active comparator arm, using only imaging. |
Primary endpoint: Operative time of surgical procedure. |
Secondary endpoints: Reduction of blood loss, proportion of postoperative adverse events, and negative tumor margins. |
Exploratory endpoints: Surgical planning ease, changes in surgical plan, and surgeon satisfaction. conditions: Sarcoma, Ewing conditions: Chondrosarcoma conditions: Osteosarcoma conditions: Fibrous Histiocytoma conditions: Fibrosarcoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: 3D Printed Anatomic Model name: CT/MRI measure: Operative time measure: Blood loss measure: Adverse Events measure: Tumor margin status sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: William Beaumont University Hospital status: RECRUITING city: Royal Oak state: Michigan zip: 48073 country: United States name: Pamela Sloan, RN, CCRP role: CONTACT phone: 248-551-6059 email: [email protected] lat: 42.48948 lon: -83.14465 facility: The Ohio State University Wexner Medical Center status: RECRUITING city: Columbus state: Ohio zip: 43212 country: United States name: Rachel Herster, BS role: CONTACT phone: 248-514-4490 email: [email protected] lat: 39.96118 lon: -82.99879 hasResults: False |
<|newrecord|> nctId: NCT06387472 id: 23-007636 briefTitle: DermAI to Evaluate Human Factor of Testing overallStatus: RECRUITING date: 2024-04-29 date: 2024-08-01 date: 2024-12-31 date: 2024-04-29 date: 2024-04-29 name: Mayo Clinic class: OTHER briefSummary: The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home. conditions: Contact Dermatitis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 150 type: ESTIMATED name: AI algorithm to evaluate photographs of skin test patch regions name: Allergen Patch measure: Classification of test site region reaction measure: Classification of test site region using a 5-point scale measure: False Positive Rate measure: False Negative Rate measure: Early termination of testing measure: Participants that removed patches early measure: Adverse events related to allergen exposure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224 country: United States name: Laura Pacheco-Spann role: CONTACT phone: 904-953-0408 email: [email protected] name: Matthew Hall, MD role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 hasResults: False |
<|newrecord|> nctId: NCT06387459 id: 2022M3C1A3090827 briefTitle: Feasibility of Fabric Orthosis for Knee Support in Elderly Gait Improvement overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-05-14 date: 2026-05-14 date: 2024-04-29 date: 2024-04-29 name: Seoul National University Hospital class: OTHER name: Ministry of Science and ICT briefSummary: This pilot clinical trial assesses the safety and feasibility of a novel fabric-type orthosis designed to mimic the knee extensor muscles and improve gait in elderly patients with mobility impairments due to conditions like sarcopenia, diabetes, or knee osteoarthritis. The study aims to test this orthosis in a real- world setting to see if it can enhance mobility and stability for elderly individuals, potentially reducing falls and improving quality of life. A total of 30 participants aged 65 and older will be recruited to use this orthosis across multiple sessions, where their gait will be analyzed under various conditions to measure the device's impact on walking speed, stability, and muscle activation. conditions: Gait conditions: Fall conditions: Orthotic Devices studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: Fabric-Type Knee Extensor Muscle-Mimicking Orthosis measure: Completion Rate measure: Dropout Rate measure: User Feedback measure: 6-Minute Walk Test measure: 10-Meter Walk Test measure: Surface Electromyography measure: Gait Analysis sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06387446 id: RB-P00044611 briefTitle: Allogeneic Valve Transplantation overallStatus: RECRUITING date: 2024-05-01 date: 2027-06-01 date: 2027-06-01 date: 2024-04-29 date: 2024-04-29 name: Boston Children's Hospital class: OTHER briefSummary: Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve. conditions: Valve Heart Disease conditions: Valve Disease, Heart conditions: Valve Disease, Aortic studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 4 type: ESTIMATED name: Valve transplant measure: Valve Regurgitation measure: Valve Annulus Growth measure: Leaflet Growth measure: Ventricular Function measure: Survival sex: ALL minimumAge: 30 Days maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Boston Children's Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Sitaram Emani, MD role: CONTACT lat: 42.35843 lon: -71.05977 hasResults: False |
<|newrecord|> nctId: NCT06387433 id: mHealth id: SG-222/R3-05/RDC/DUHS/1478 type: OTHER_GRANT domain: National Institutes of Health Pakistan briefTitle: Effectiveness of an mHealth Mobile App acronym: mHealth overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-20 date: 2025-08 date: 2025-08 date: 2024-04-29 date: 2024-04-29 name: Dow University of Health Sciences class: OTHER name: National Institutes of Health (NIH) briefSummary: Type II diabetes is a serious challenge for Pakistan. Not using medications properly increases healthcare costs and diabetes-related deaths. A mobile app in local language can improve medication adherence and self-management among diabetics. Therefore, in this 18 months long study we will develop a diabetes-related mobile application in Urdu, and will conduct a trial to assess whether it improves medication compliance and self-management, and how much economical this app would be compared to the usual standard of care for type II diabetics in Pakistan. This trial will be conducted at the National Institute of Diabetes and Endocrinology Karachi. The study participants will be divided in two groups. Only one group will use this application. We will measure medication compliance and self-management through diabetes-specific blood test and self-reporting questionnaires between two groups. We will also determine how much economic costs would be saved by using this app to improve medication compliance conditions: Type II Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 160 type: ESTIMATED name: mobile app use measure: adherence to medication measure: self-management among diabetics measure: Intervention usability measure: economic effectiveness of the app sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institute of Diabetes and Endocrinology city: Karachi state: Sindh country: Pakistan lat: 24.8608 lon: 67.0104 hasResults: False |
<|newrecord|> nctId: NCT06387420 id: AK117-206 briefTitle: A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2026-04 date: 2027-04 date: 2024-04-29 date: 2024-04-29 name: Akeso class: INDUSTRY briefSummary: This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML. conditions: ACUTE MYELOID LEUKEMIA; AML studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: AK117 name: Azacitidine name: Venetoclax name: Placebo measure: Phase 1b: Number of participants with dose limiting toxicity (DLT) measure: Phase 1b/2: Number of participants with adverse events (AEs) measure: Phase 1b/2: Composite complete remission rate (CCR) measure: Overall response rate (ORR) measure: Time to response (TTR) measure: Time to CCR (TTCCR) measure: Duration of response (DoR) measure: Duration of CCR (DoCCR) measure: Rate of CCR Without Minimal Residual Disease (CCR MRD-) measure: Event-free survival (EFS) measure: Overall survival (OS) measure: Peak of Serum Concentration (Cmax) measure: Anti-drug antibody (ADA) measure: Receptor occupancy (RO) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College city: Tianjin country: China name: Jianxiang Wang role: CONTACT lat: 39.14222 lon: 117.17667 hasResults: False |
<|newrecord|> nctId: NCT06387407 id: 2024037K briefTitle: Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-10 date: 2025-11-25 date: 2024-04-29 date: 2024-04-29 name: The Affiliated Hospital Of Guizhou Medical University class: OTHER briefSummary: According to published studies, the effects of genetic polymorphisms in the ABCB1 and CES1 genes on the blood concentration of dabigatran are controversial, and it is not clear whether dabigatran dosage and dosing intervals need to be adjusted according to genotype or other covariates in Chinese subjects. For these purposes, we will include patient demographics, genetic polymorphisms, and PK data based on a population pharmacokinetic study of dabigatran ester in healthy Chinese subjects to analyze the effect on dabigatran pharmacokinetics. |
The aim of this study was to develop a population pharmacokinetic model to understand the relationship between dabigatran-related genes and dabigatran plasma levels after a single oral dose in healthy Chinese subjects and patients, and to analyze the effects of genetic variation on the efficacy and safety of dabigatran etexilate. conditions: Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED name: Dabigatran Etexilate 150mg measure: Plasma drug concentration sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06387394 id: M21-416 briefTitle: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence overallStatus: RECRUITING date: 2024-04-22 date: 2025-12-27 date: 2026-01-26 date: 2024-04-29 date: 2024-04-29 name: AbbVie class: INDUSTRY briefSummary: The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP). |
BOTOX is being investigated for the treatment of Muscle Masseter Prominence. In Period 1, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment, placebo or BOTOX. There is a 1 in 4 chance that participants will be assigned to placebo. In Period 2, eligible participants can receive an optional open-label retreatment of BOTOX. Approximately 200 adult participants with MMP will be enrolled in the study at approximately 20 sites in the United States. |
Participants will receive intramuscular injections across both the right and left masseter muscle of either BOTOX or placebo on Day 1. Participants who are eligible for re-treatment will be given BOTOX injections on either the Day 180, 210, 240, or 270 visit and will be followed up for up to 6 months. |
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, and completing questionnaires. conditions: Masseter Muscle Prominence studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: BOTOX name: Placebo measure: Composite Achievement of MMP Severity Improvement and at Least a 2-Grade Improvement from Baseline by Both Investigator-Rated MMPS and Participant-Rated MMPS-P measure: Number of Participants with Adverse Events (AEs) measure: Percentage of Participants Achieving Investigator-Rated MMPS Improvement Over Time measure: Percentage of Participants Achieving Participant-Rated MMPS-P Improvement Over Time measure: Percentage of Participants who Responded as "Very satisfied" or "Satisfied" on the Lower Facial Shape Questionnaire - Treatment Satisfaction Assessment (LFSQ-TXSAT) measure: Percentage of Participants who Responded as "Much improved" or "Moderately improved" on the MMP Participant Self-Assessment of Change (MMP-PSAC) measure: Percentage of Participants who Responded as "Not at all bothered" or "A little bothered" on the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP) measure: Change from Baseline in Lower Facial Shape Questionnaire-Impact Assessment (LFSQ-IA) Summary Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Delricht Research /ID# 249825 status: RECRUITING city: New Orleans state: Louisiana zip: 70115 country: United States lat: 29.95465 lon: -90.07507 facility: Clarkston Dermatology /ID# 248888 status: RECRUITING city: Clarkston state: Michigan zip: 48346 country: United States lat: 42.73586 lon: -83.41883 hasResults: False |
<|newrecord|> nctId: NCT06387381 id: CYYY-KY-2024-048-01 briefTitle: 68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease overallStatus: RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2026-12-31 date: 2024-04-29 date: 2024-04-29 name: First Affiliated Hospital of Chongqing Medical University class: OTHER briefSummary: As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases. conditions: PSMA conditions: FAP conditions: Positron-Emission Tomography studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: 68Ga-PSFA measure: Diagnostic efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Chongqing Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400016 country: China name: Xiaoyang Zhang, PhD role: CONTACT phone: 023-89011755 email: [email protected] lat: 29.56278 lon: 106.55278 hasResults: False |
<|newrecord|> nctId: NCT06387368 id: HE-202303 briefTitle: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-03 date: 2028-08 date: 2024-04-29 date: 2024-04-29 name: Health Science Center of Xi'an Jiaotong University class: OTHER name: LinkDoc Technology (Beijing) Co. Ltd. name: Huazhong University of Science and Technology briefSummary: This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer. conditions: Pancreatic Cancer Non-resectable studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 488 type: ESTIMATED name: Huaier Granule name: Capecitabine measure: Overall survival measure: Objective response rate measure: Progression free survival measure: Conversion surgery rate measure: The incidence and severity of adverse events (AE) and severe adverse events (SAE) measure: The incidence and severity of ADR, severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06387355 id: SURG-006-23S briefTitle: Diagnosis and Treatment of CAD in Severe PAD After Lower Extremity Revascularization acronym: CAD in sPAD overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2027-08-01 date: 2029-08-01 date: 2024-04-29 date: 2024-04-29 name: VA Office of Research and Development class: FED briefSummary: Peripheral artery disease, lack or blood flow to the legs, has a high prevalence in the Veteran population. In patients with severe peripheral artery disease that requires an endovascular or surgical intervention for lower leg revascularization, the long-term mortality of approximately 50% is worse that most cancers. The goal of this study is to develop a management strategy to improve cardiovascular outcomes in this high-risk peripheral artery disease population after lower extremity revascularization. conditions: Peripheral Artery Disease conditions: Coronary Artery Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This will be a parallel interventional model to assign participants to a treatment strategy in a clinical study primaryPurpose: TREATMENT masking: NONE count: 450 type: ESTIMATED name: Coronary computed topography (CT) angiography with FFR-CT measure: Major adverse cardiovascular events (MACE) measure: Cardiovascular-related death measure: Myocardioal infarction measure: All-cause mortality measure: Amputation-free survival sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rocky Mountain Regional VA Medical Center, Aurora, CO city: Aurora state: Colorado zip: 80045 country: United States name: Clay Quint, MD PhD role: CONTACT phone: 210-606-2940 email: [email protected] name: Clay Quint, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 39.72943 lon: -104.83192 facility: North Florida/South Georgia Veterans Health System, Gainesville, FL city: Gainesville state: Florida zip: 32608-1135 country: United States name: Salvatore Scali, MD role: CONTACT phone: 352-376-1611 lat: 29.65163 lon: -82.32483 facility: Louis Stokes VA Medical Center, Cleveland, OH city: Cleveland state: Ohio zip: 44106-1702 country: United States name: Michael Rosenbaum, MD role: CONTACT phone: 216-791-3800 lat: 41.4995 lon: -81.69541 facility: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA city: Pittsburgh state: Pennsylvania zip: 15240 country: United States name: Edith Tzeng, MD role: CONTACT phone: 866-482-7488 lat: 40.44062 lon: -79.99589 facility: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN city: Nashville state: Tennessee zip: 37212-2637 country: United States name: John Curci, MD role: CONTACT phone: 615-327-4751 lat: 36.16589 lon: -86.78444 facility: VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX city: Dallas state: Texas zip: 75216-7167 country: United States name: Shirling Tsai, MD role: CONTACT phone: 469-797-2100 lat: 32.78306 lon: -96.80667 facility: VA Puget Sound Health Care System Seattle Division, Seattle, WA city: Seattle state: Washington zip: 98108-1532 country: United States name: Gale Tang, MD role: CONTACT phone: 800-329-8387 lat: 47.60621 lon: -122.33207 hasResults: False |
<|newrecord|> nctId: NCT06387342 id: CF102-222PC briefTitle: Namodenoson Treatment of Advanced Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-07-15 date: 2026-07-15 date: 2026-12-15 date: 2024-04-29 date: 2024-04-29 name: Can-Fite BioPharma class: INDUSTRY briefSummary: This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients. conditions: Pancreatic Adenocarcinoma conditions: Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open-label study primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Namodenoson 25mg measure: Adverse Events measure: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline measure: Objective response rate measure: Progression free survival measure: Disease control rate measure: Duration of response measure: Overall survival measure: Quality of Life evaluation with EORTC QLQ-C30 measure: Quality of Life evaluation with EORTC QLQ-PAN26 measure: Pharmacokinetics of namodenoson: Cmax measure: Pharmacokinetics of namodenoson: Cmin measure: Pharmacokinetics of namodenoson: AUC(0-12) measure: Cancer antigen 19-9 (CA 19-9) measure: Carcinoembryonic Antigen (CEA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rabin Medical Center Institute of Oncology city: Petach Tikva zip: 49100 country: Israel name: Salomon M Stemmer, MD role: CONTACT lat: 32.08707 lon: 34.88747 hasResults: False |
<|newrecord|> nctId: NCT06387329 id: WRNMMC-2023-0438 briefTitle: Bladder Botox UTI Antibiotic Prophylaxis overallStatus: RECRUITING date: 2024-04-04 date: 2025-06-30 date: 2025-06-30 date: 2024-04-29 date: 2024-04-29 name: Walter Reed National Military Medical Center class: FED briefSummary: Overactive bladder (OAB) is a common condition with a prevalence of 17% in the general population that significantly affects quality of life. Intradetrusor onabotulinumtoxinA injections are an advanced therapy for OAB as well as interstitial cystitis/bladder pain syndrome (IC/BPS). The most common adverse event following intradetrusor injection of onabotulinumtoxinA in urinary tract infection (UTI), which occurs in 8.6-48.1% of patients. To prevent UTIs, patients are given a course of antibiotics, however the ideal prophylactic regimen has not been determined for the timing, duration, and type of antibiotic. Four retrospective studies in the literature address this question with variable conclusions, and there are no prospective studies. Identifying the ideal regimen is important for preventing UTIs as well as minimizing antibiotic use to prevent adverse effects and development of antibiotic resistance. |
The population to be studied will be female patients 18 years and older who are patients of the urogynecology and urology clinics at Walter Reed National Military Medical Center with a diagnosis of OAB or IC/BPS and have chosen to be treated with intradetrusor onabotulinumtoxinA injections. It will be a non-blinded randomized controlled noninferiority trial in which the patients are randomly placed into 2 groups. The first group will receive a 3 day course of twice daily oral nitrofurantoin 100mg starting at the time of the procedure, and the second group will receive a single dose of 100mg oral nitrofurantoin at the time of the procedure. |
The patients will be screened at the clinic at the time that they schedule their intradetrusor onabotulinumtoxinA injection appointment or by phone 1-2 weeks prior to their procedure. If the patient agrees to participate in the study then they will be instructed to give a urine sample for urinalysis and culture 1 week prior to the procedure appointment to exclude existing UTI. If a UTI is diagnosed at this time they must complete treatment prior to the procedure or will need to reschedule their procedure. On the day of the procedure patients will receive the clinic standard 10ml of 2% viscous lidocaine through the urethra 10-20 minutes prior to the procedure, and may be offered 5-10mg oral diazepam at the discretion of the treating physician. All patients will be given 200mg of phenazopyridine and 100mg of nitrofurantoin prior to the initiation of the procedure. The procedure will take place as directed by the treating physician per standard operating procedure. |
A urinalysis and urine culture will be placed for all study participants at time of their procedure appointment in case they have symptoms of UTI, and they will be instructed to follow up with the research team by phone if they have concerns for a UTI. Patients will be contacted 30-45 days after the procedure by phone, email, or message through genesis and asked about any UTI symptoms, UTI diagnoses and secondary outcomes during the 30 days following the procedure. Data will be analyzed for the primary outcome of UTI rates in the 30 days following intradetrusor onabotulinumtoxinA injection. conditions: Overactive Bladder conditions: Bladder Pain Syndrome studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Nonblinded, randomized, noninferiority trial of single dose nitrofurantoin vs 3 day twice daily course of nitrofurantoin for prevention of post-procedure urinary tract infections after intradetrusor onabotulinumtoxinA injections for OAB and IC/BPS. primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Nitrofurantoin 100 MG measure: Urinary tract infection measure: Urinary tract infection symptoms measure: Urinary retention measure: Adverse effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Walter Reed National Military Medical Center status: RECRUITING city: Bethesda state: Maryland zip: 20899 country: United States name: Jordan Gisseman, MD role: CONTACT phone: 301-400-2468 email: [email protected] lat: 38.98067 lon: -77.10026 hasResults: False |
<|newrecord|> nctId: NCT06387316 id: 2023-1526 briefTitle: Cephalic Phase Responses to Nutritive and Non-Nutritive Sweeteners overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-26 date: 2024-04-17 date: 2025-03-30 date: 2024-04-29 date: 2024-04-29 name: Purdue University class: OTHER briefSummary: This study will focus on changes in blood sugar in response to tasting different types of sweeteners using continuous glucose monitoring (CGM) technology. conditions: Pre Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: solutions are coded whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: No Oral Stimulation name: Oral water stimulation name: Oral Salt Stimulation name: Oral Sucralose Stimulation name: Oral Sucrose stimulation measure: Blood glucose concentration sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Purdue University city: West Lafayette state: Indiana zip: 47907 country: United States lat: 40.42587 lon: -86.90807 hasResults: False |
<|newrecord|> nctId: NCT06387303 id: HSR230492 briefTitle: Pain Control and Quality of Recovery After Intravenous Methadone Versus Intrathecal Morphine in Major Abdominal Surgery overallStatus: NOT_YET_RECRUITING date: 2024-05-12 date: 2026-05-11 date: 2026-05-11 date: 2024-04-29 date: 2024-04-29 name: University of Virginia class: OTHER briefSummary: Moderate to severe postoperative pain is relatively common after major abdominal surgery and is associated with less than optimal surgical experience, poor quality of recovery, and development of persistent postsurgical pain. Opioids remain a major component of postoperative pain management. Side effects of opioids used for treatment of postoperative pain include constipation, pruritus, nausea, and vomiting.1,2 Enhanced recovery after surgery (ERAS) protocols involve utilization of multimodal analgesia. Analgesic techniques used include epidural analgesia, nerve blocks, and Intrathecal (IT) administration of morphine. IT morphine reduces postoperative opioid requirement for 18-24 hours after major abdominal surgery and reduces hospital length of stay (LOS) compared with epidural analgesia.3,4 Significant number of patients that receive IT morphine still experience moderate to severe postoperative pain.5 Additionally, many patients refuse the invasive procedure or cannot receive IT morphine due to procedure contraindications; thrombocytopenia and/or coagulopathy.6 |
Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties.7-9 It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery.10-13 Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery.14,15 IV methadone has, however, never been compared with IT morphine as a postoperative analgesic. |
Our hypothesis is that intravenous (IV) methadone is non-inferior to IT morphine in patients who undergo major abdominal surgery. It offers the advantage of being a noninvasive analgesic, modality that may contribute to decreasing opioid consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery. conditions: Pain, Postoperative studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: a single blind study primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: PARTICIPANT count: 218 type: ESTIMATED name: Methadone name: Morphine measure: Quality of Recovery 15 score measure: Overall Benefits of Analgesic Score (OBAS) measure: morphine milligram equivalent measure: Verbal Rating Scale (VRS) pain scores measure: McGill Pain questionnaire score measure: Verbal Rating Scale (VRS) pain scores sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Virginia city: Charlottesville state: Virginia zip: 22908-0710 country: United States lat: 38.02931 lon: -78.47668 hasResults: False |
<|newrecord|> nctId: NCT06387290 id: 00172836 briefTitle: Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2030-05-01 date: 2030-05-01 date: 2024-04-29 date: 2024-04-29 name: University of Utah class: OTHER name: Rutgers University briefSummary: The primary aim of this implementation-effectiveness trial is to examine the effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) and patient-centered chronic pain management visits in primary care as interventions to reduce chronic pain, improve quality of life, and reduce opioid-related harms among chronic pain patients on long-term opioid therapy. conditions: Chronic Pain conditions: Prescription Opioid Misuse conditions: Substance-Related Disorders conditions: Pain conditions: Narcotic-Related Disorders conditions: Chemically-Induced Disorders conditions: Mental Disorders conditions: Opioid-Related Disorders conditions: Neurologic Manifestations studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Hybrid implementation-effectiveness trial primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigators, study staff, and statistician will be blinded to treatment condition. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Mindfulness Oriented Recovery Enhancement name: Patient-Centered Chronic Pain Management Visits measure: Opioid Misuse measure: Chronic Pain measure: Change in Quality of Life measure: Opioid Dosing measure: Opioid Craving measure: PTSD Symptoms measure: Depression measure: Generalized Anxiety measure: Decentering measure: Mindful Reappraisal of Pain Sensations measure: Savoring measure: Reappraisal sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rutgers University Primary Care Clinics city: New Brunswick state: New Jersey zip: 08901 country: United States name: Thanusha Puvananayagam, MPH role: CONTACT phone: 732-235-4341 email: [email protected] name: Taylor Scott, MSW role: CONTACT phone: 732-235-7453 email: [email protected] name: Nina Cooperman, PsyD role: PRINCIPAL_INVESTIGATOR lat: 40.48622 lon: -74.45182 facility: University of Utah Primary Care Clinics city: Salt Lake City state: Utah zip: 84112 country: United States name: Kelly A Hendrickson, MS role: CONTACT phone: 801-585-6354 email: [email protected] name: Layla Lincoln, BA role: CONTACT phone: 801-581-7508 email: [email protected] name: Eric L Garland, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.76078 lon: -111.89105 hasResults: False |
<|newrecord|> nctId: NCT06387277 id: RV1551P20220376 briefTitle: Re-epithelialization Efficacy Evaluation of Cosmetic Product RV1551P vs Non-treated Forearm of Healthy Adult Women overallStatus: COMPLETED date: 2022-09-19 date: 2022-12-12 date: 2022-12-12 date: 2024-04-29 date: 2024-04-29 name: Pierre Fabre Dermo Cosmetique class: INDUSTRY briefSummary: The aim of this study was to evaluate the impact of the product RV1551P GB3224 on skin microbiota during wound healing process, based on swab samples collected from lesion areas using an epidermally ablated skin model of erbium YAG laser. conditions: Healthy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 21 type: ACTUAL name: RV1551P GB3224 measure: Time to re-epithelialization as assessed by in vivo examination by the investigator and standardized photographs taken with a C Cube Camera® measure: Skin microbiota diversity from swab samples. measure: Skin microbiota composition from swab samples. measure: Metabolomic analysis from swab samples sex: FEMALE minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT facility: Skin Research Centre city: Toulouse state: Haute-Garonne zip: 31300 country: France lat: 43.60426 lon: 1.44367 hasResults: False |
<|newrecord|> nctId: NCT06387264 id: 2022PHC032 briefTitle: Compont - Varicose Veins of the Lower Extremities overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-11 date: 2024-04 date: 2024-12 date: 2024-04-29 date: 2024-04-29 name: Peking University People's Hospital class: OTHER name: Peking University First Hospital name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine name: First Affiliated Hospital Xi'an Jiaotong University name: Liaocheng People's Hospital name: The Second Affiliated Hospital of Chongqing Medical University briefSummary: The purpose of this clinical trial is to evaluate the effectiveness and safety of Medical Adhesive produced by Beijing Compont Medical Devices Co., Ltd. in the treatment of varicose veins in the lower extremities. |
The main questions it aims to answer is: What medical problems do participants have when using tissue glue? Researchers will compare Medical Adhesive to ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by Medtronic Inc. to see if Medical Adhesive works to treat varicose veins in the lower extremities. |
Participants will: |
Treated with closed varicose veins of the lower extremity by Medical Adhesive or ClosureFast. |
Return to the hospital at 1, 12, and 24 weeks postoperatively for Doppler ultrasound, and at 4, 12, 24 weeks postoperatively for venous scoring. conditions: Varicose Veins of Lower Limb studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 188 type: ACTUAL name: Medical Adhesive name: ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter measure: Clinical success rate measure: Technical success rate measure: Target vascular closure rate at 12 weeks after operation. measure: Clinical signs measure: Venous Clinical Severity Score (VCSS) measure: Aberdeen Varicose Vein Questionnaire (AVVQ) measure: Operation duration measure: Evaluation of product performance sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital city: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06387251 id: 2023-11-437-0003 briefTitle: Assess the Effects of a 30 Day-wellness Program on Digestive Health, Weight and Overall Well-being overallStatus: COMPLETED date: 2024-01-29 date: 2024-02-29 date: 2024-02-29 date: 2024-04-29 date: 2024-04-29 name: Peryam & Kroll Research Corporation class: OTHER name: Alticor Inc. briefSummary: The digestive system is a pivotal component of human health, playing a crucial role in the absorption of nutrients, elimination of waste, and even influencing mental well-being. Poor digestive health can significantly impact one's quality of life and overall well-being. Issues such as bloating, constipation, or imbalanced gut microbiome can affect one's overall well-being. Moreover, the gut-brain connection underscores how digestive health can affect mental well-being. The gut can contribute to serotonin and energy production thus influencing one's mood, energy levels and cognitive functions, affecting one's emotional stability. Additionally, inadequate nutrient absorption from an imbalanced digestive system may lead to suboptimal health, weakening the body and causing fatigue. Overall, maintaining good digestive health is crucial not only for physical comfort but also for normal metabolism, immune function, cognitive abilities, sleep and skin health, ultimately enhancing the overall quality of life. Products designed by the sponsor contains a blend of ingredients recognized for their potential benefits in promoting digestive health (including prebiotics, probiotics, postbiotics, plant-based extracts and plant-based protein). Furthermore, it is well established in the literature that diet, exercise, hydration and mindfulness all impact our gut health and overall well-being. Therefore, this scientific study seeks to validate the efficacy of the combination of products and life-style changes by assessing its impact on gut health and related health aspects like weight, metabolic health, fitness level, energy/fatigue levels, satiety/hunger, food cravings, cognitive abilities and overall well-being. conditions: Digestive Health studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 150 type: ACTUAL name: 30 day wellness program measure: Bristol Stool Scale measure: Digestive symptom frequency questionnaire measure: Waist Circumference measure: Improvements in sleep measure: Improvements in stress measure: Fitness Level measure: Satiety Responsiveness and Hunger measure: Craving Intensity measure: Cognitive Abilities measure: Fatigue measure: Skin Appearance measure: General Health measure: Program Feedback sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wilkins Research city: Chattanooga state: Tennessee zip: 37421 country: United States lat: 35.04563 lon: -85.30968 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-12-11 uploadDate: 2024-03-07T13:19 filename: ICF_000.pdf size: 144142 hasResults: False |
<|newrecord|> nctId: NCT06387238 id: PSMA-mHSPC briefTitle: Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-06-30 date: 2024-04-29 date: 2024-04-29 name: Peking University First Hospital class: OTHER briefSummary: 1. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a PSMA PET whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis. |
2. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a multivariable model will be constructed using quantitative parameters of PSMA PET/CT imaging, pre-treatment gene status, PSA, GS/ISUP and other clinical pathological parameters to further achieve accurate patient classification, guide treatment, and evaluate prognosis. conditions: Prostate Adenocarcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Patients With Metastatic Hormone Sensitive Prostate Cancer, will receive pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy. primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: PSMA PET/CT measure: rPFS measure: PSA-PFS measure: OS sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06387225 id: RC23_0248 briefTitle: Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients acronym: HYPERION-2 overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-12-01 date: 2026-12-01 date: 2024-04-26 date: 2024-04-29 name: Nantes University Hospital class: OTHER briefSummary: Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.